Elevation Oncology Competitors and Similar CompaniesClear all
Elevation Oncology's competitors and similar companies include StemMed, Tvardi Therapeutics, Halozyme Therapeutics and Puma Biotechnology.
 Elevation Oncology Elevation Oncology is a biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers. |  StemMed StemMed is a pharmaceutical development and testing company that provides pre-clinical drug testing services using a panel of patient-derived xenograft (PDX) models of breast and pancreatic cancers. |  Tvardi Therapeutics Tvardi Therapeutics is a biotechnology company developing medicines for the treatment of cancer, chronic inflammation, and fibrosis. |  Halozyme Therapeutics Halozyme Therapeutics is a biotechnology company focused on developing and commercializing cancer therapies that target the tumor microenvironment. |  Puma Biotechnology Puma Biotechnology acquires and develops innovative products for the treatment of various forms of cancer. | |
Founding Date | Founding Date 2019 | Founding Date 2009 | Founding Date 2017 | Founding Date 1998 | Founding Date 2010 |
Type | Type Public | Type Private | Type Private | Type Public | Type Public |
Tags | |||||
Locations | Locations New York, US HQ | Locations Houston, US HQ | Locations Houston, US HQ Houston, US | Locations San Diego, US HQ | Locations Los Angeles, US HQ |
Employees | Employees 8 | Employees 2 | Employees 19 | Employees 373157% increase | Employees 27214% decrease |
Valuation ($) | Valuation ($) 35.1 m | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 6.4 b | Valuation ($) 136.8 m |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) $1.4b (FY, 2025) | Revenue (est.) $228.4m (FY, 2025) |
Cost of goods | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A | Cost of goods $228.8m (FY, 2025) | Cost of goods $58.2m (FY, 2025) |
Gross profit | Gross profit N/A | Gross profit N/A | Gross profit N/A | Gross profit $1.2b (FY, 2025) | Gross profit $170.2m (FY, 2025) |
Net income | Net income ($44.5m) (FY, 2024) | Net income N/A | Net income N/A | Net income $316.9m (FY, 2025) | Net income N/A |
Funding | |||||
Total funding raised | Total funding raised $ 97.5m | Total funding raised N/A | Total funding raised $ 88m | Total funding raised $ 171.9m | Total funding raised $ 172m |
For sources of this data, please see the company profile
View Company Profiles
StemMed
HQ
Houston, US
Employees
2
StemMed is a pharmaceutical development and testing company that provides pre-clinical drug testing services using a panel of patient-derived xenograft (PDX) models of breast and pancreatic cancers.
View companyTvardi Therapeutics
HQ
Houston, US
Employees
19
Tvardi Therapeutics is a biotechnology company developing medicines for the treatment of cancer, chronic inflammation, and fibrosis.
View companyHalozyme Therapeutics
HQ
San Diego, US
Employees
373
Halozyme Therapeutics is a biotechnology company focused on developing and commercializing cancer therapies that target the tumor microenvironment.
View companyPuma Biotechnology
HQ
Los Angeles, US
Employees
272↓ 14% decrease
Puma Biotechnology acquires and develops innovative products for the treatment of various forms of cancer.
View company